Trump's Psychedelics Executive Order: What It Means Globally (April 2026)

On 14 April 2026, Donald Trump signed a presidential executive order that fundamentally reshapes federal US psychedelics policy. Joe Rogan stood alongside him, a podcaster who has spent years amplifying the case for psilocybin research and ibogaine therapy for US veterans. What looked unthinkable a decade ago now plays out in the Oval Office.

Last updated: April 2026
This analysis tracks the federal psychedelics executive order and what it means for Europe and the wider global psychedelic landscape.

At Next Level Smart Shop we have followed the science and culture around psilocybin, microdosing and ethnobotanical traditions since 2010. This policy shift lands squarely in our field. It also lands on every reader who treats psychedelics as a serious topic rather than a punchline.

What the order actually covers

The order focuses on three pillars, based on the initial readout. Federal agencies including the FDA and the Veterans Administration are directed to accelerate clinical research into psilocybin, MDMA and ibogaine. Additional funding flows toward veterans suffering from PTSD, the community whose advocacy has shaped the political heat of this file. And a formal reconsideration of Schedule I classifications lands on the agenda.

What the order does not do: it does not legalise psychedelics nationally. No presidential signature can reach that far. But the symbolism of a sitting US president setting the tempo on this topic is not to be underestimated. Veteran groups and researchers could not secure a conversation at this level for years.

Joe Rogan's presence at the signing underlines another story. Rogan spent the last decade discussing ibogaine protocols for Navy SEALs with millions of listeners well before the White House took the topic seriously. The gap between official science and lived experience has just been formally bridged.

The science behind the political shift

This moment did not appear from nowhere. Federal policy is shifting because the clinical data has become too consistent to ignore.

In 2022 the New England Journal of Medicine published a double-blind trial by Goodwin and colleagues. A single dose of psilocybin produced significantly greater symptom reduction in treatment-resistant depression than a low-dose control (Goodwin et al., 2022). In 2023 a large JAMA study by Raison and colleagues showed that a single psilocybin dose improved depression scores in adults during a depressive episode, with effects sustained over weeks (Raison et al., 2023).

For MDMA, Nature Medicine published Mitchell and colleagues' Phase 3 results in 2023. Of participants with moderate to severe PTSD, 86.5 percent showed clinically meaningful improvement (Mitchell et al., 2023). The FDA rejected the Lykos Therapeutics application in 2024 over methodological concerns, yet the underlying data still stands.

These studies share a framing. They treat psychedelics as serious tools, not recreational risks. That is exactly the framing the executive order now adopts.

Europe is watching: from Prague to Amsterdam

The American shift does not stand alone. Czech Republic formally opened the door to regulated psilocybin therapy earlier in 2026, a story we covered at length in our analysis of the Czech model. Australia did something comparable in 2023. Switzerland has run a limited therapeutic programme around MDMA and LSD for years.

A pattern now connects European capitals. Countries willing to take the first step are no longer treated as exotic outliers. They are pioneers. The Netherlands holds a distinctive position in this story. Magic truffles are legally available, microdosing protocols sit in the public domain, and psilocybin research continues quietly through universities in Maastricht and Leiden.

Realism matters. Dutch policy remains cautious. Fresh mushrooms were banned in 2008. An American shift does not mean The Hague drafts a similar order tomorrow. But the international legitimacy of the research expands, and that benefits everyone working seriously in this space.

Microdosing leaves the shadows

One overlooked consequence of this order: microdosing matures as a topic. Our earlier piece on the microdose revolution traced how thousands of people now attempt to improve daily functioning through sub-perceptual psilocybin doses. Silicon Valley turned it into a cultural phenomenon. Now the White House follows.

For Dutch context this matters because microdosing with magic truffles has been accessible here for longer. Anyone starting a structured protocol often reaches for a pre-portioned microdosing starter pack. This avoids the weighing hassle and ensures consistent doses, which is exactly the feature every scientific protocol insists on.

American attention also drags microdosing research along. The call for rigorous randomised trials on sub-perceptual psilocybin dosing has been building for years, and the executive order will only accelerate that push. We covered the cultural side of that shift in our piece on how nature invented psilocybin twice, which sits surprisingly close to this policy story.

Set, setting, and the art of careful exploration

A detail easily lost in the political noise: psychedelics demand serious preparation. Set (your inner state) and setting (the environment around the experience) are not sixties slogans. They form the spine of every clinical trial currently persuading the scientific world.

With a stronger truffle like Psilocybe Atlantis or the intense Psilocybe Utopia, a quiet and safe room is not a luxury. A sober, trusted presence (a tripsitter in short) marks the difference between a formative experience and an avoidable discomfort. First-time explorers should start gentler, perhaps with Psilocybe Mexicana.

For a full introduction, read our magic truffles guide 2026. It covers everything needed to prepare properly.

What actually changes for you

Short and honest: for Dutch consumers nothing changes legally in the short term. Magic truffles remain legal, fresh mushrooms remain banned, and microdosing stays in the grey zone where personal responsibility applies.

What shifts instead:

• International acceptance of psychedelic research grows. That means more publications, more funding and more insight
• Cultural stigma continues to recede. Something signed by a US president is no longer a countercultural curiosity
• Therapeutic applications move closer. Dutch clinics experimenting with psilocybin therapy can lean on far more international data
• Knowledge about set and setting reaches more people. The mystique of "how do you do this right" is replaced by structured protocols

The new scientific consensus in three layers

Why Next Level Smart Shop?

Last update: April 2026 | Next Level Smart Shop